Patents by Inventor Susan Demo
Susan Demo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7413870Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: GrantFiled: December 21, 2001Date of Patent: August 19, 2008Assignee: Rigel Pharmaceuticals, IncorporatedInventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
-
Patent number: 7358040Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.Type: GrantFiled: December 21, 2001Date of Patent: April 15, 2008Assignee: Rigel Pharmaceuticals, IncorporatedInventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
-
Publication number: 20060276489Abstract: The invention relates to the inhibition of tubulin polymerization. The invention provides compounds and methods for inhibiting tubulin polymerization. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: ApplicationFiled: May 9, 2006Publication date: December 7, 2006Applicant: Rigel Pharmaceuticals, Inc.Inventors: Dane Goff, Mark Bennett, Susan Demo
-
Publication number: 20060193844Abstract: Improved regimens for administering proteasome inhibitors are described, wherein proteasome inhibition is more sustained relative to certain current regimens which permit substantial recovery of proteasome activity between doses of inhibitor.Type: ApplicationFiled: February 28, 2006Publication date: August 31, 2006Applicant: Proteolix, Inc.Inventors: Mark Bennett, Christopher Kirk, Susan Demo
-
Patent number: 7071190Abstract: The invention relates to the inhibition of tubulin polymerization. The invention provides compounds and methods for inhibiting tubulin polymerization. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: GrantFiled: February 18, 2003Date of Patent: July 4, 2006Assignee: Rigel Pharmaceuticals, Inc.Inventors: Dane Goff, Mark K. Bennett, Susan Demo
-
Publication number: 20060088471Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus, such as a detectable label. Along with therapeutic utilities, these peptide based compounds can be used in assays useful for screening, monitoring, diagnostic and/or dosing purposes.Type: ApplicationFiled: October 19, 2005Publication date: April 27, 2006Applicant: Proteolix, Inc.Inventors: Mark Bennett, Tonia Buchholz, Susan Demo, Guy Laidig, Evan Lewis, Mark Smyth
-
Patent number: 7005254Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding LETM1 (“leucine zipper EF hand transmembrane receptor”), which is involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of LETM1 and LETM1 related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation.Type: GrantFiled: May 31, 2002Date of Patent: February 28, 2006Assignee: Rigel Pharmaceuticals, IncorporatedInventors: Susan Demo, Yasumichi Hitoshi, Denise Pearsall
-
Publication number: 20030225112Abstract: The invention relates to the inhibition of tubulin polymerization. The invention provides compounds and methods for inhibiting tubulin polymerization. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.Type: ApplicationFiled: February 18, 2003Publication date: December 4, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Dane Goff, Mark K. Bennett, Susan Demo
-
Publication number: 20030040001Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding LETM1 (“leucine zipper EF hand transmembrane receptor”), which is involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, siRNA, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of LETM1 and LETM1 related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation.Type: ApplicationFiled: May 31, 2002Publication date: February 27, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Susan Demo, Yasumichi Hitoshi, Denise Pearsall
-
Publication number: 20030027756Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.Type: ApplicationFiled: December 21, 2001Publication date: February 6, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
-
Publication number: 20030027167Abstract: The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding MRE 11, which is a protein involved in modulation of cellular proliferation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, and ribozymes, that modulate cellular proliferation via modulation of MRE 11; as well as to the use of expression profiles and compositions in diagnosis and therapy related to modulation of cellular proliferation.Type: ApplicationFiled: December 21, 2001Publication date: February 6, 2003Applicant: Rigel Pharmaceuticals, Inc.Inventors: Yasumichi Hitoshi, Susan Demo, Yonchu Jenkins
-
Patent number: 5955354Abstract: A novel protein which interacts with ras p21, has been identified. This protein, RGL, shares 69% amino acid homology with ral guanine nucleotide dissociation stimulator (ralGDS). ralGDS was also found to bind ras p21. The ras p21-interacting domain of RGL (RID) bound to ras p21 through the effector loop of ras p21. Polypeptide and polynucleotide compositions of the RGL protein are provided as well as methods for implementing the diagnostic and therapeutic uses of these compositions. The uses include isolating effector proteins of ras p21 and modulating ras activity.Type: GrantFiled: March 20, 1995Date of Patent: September 21, 1999Assignee: The Regents of the University of CaliforniaInventors: Lewis T. Williams, Susan Demo